NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
0.7700
+0.0400 (5.48%)
At close: Mar 25, 2026, 4:00 PM EDT
0.7900
+0.0200 (2.60%)
After-hours: Mar 25, 2026, 7:37 PM EDT
NeuroSense Therapeutics Employees
NeuroSense Therapeutics had 17 employees as of December 31, 2024. The number of employees decreased by 1 or -5.56% compared to the previous year.
Employees
17
Change (1Y)
-1
Growth (1Y)
-5.56%
Revenue / Employee
n/a
Profits / Employee
-$509,294
Market Cap
25.72M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 17 | -1 | -5.56% |
| Dec 31, 2023 | 18 | 4 | 28.57% |
| Dec 31, 2022 | 14 | 3 | 27.27% |
| Dec 31, 2021 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Barinthus Biotherapeutics | 105 |
| IGC Pharma | 70 |
| Vistagen Therapeutics | 59 |
| Cue Biopharma | 41 |
| Senti Biosciences | 34 |
| Boundless Bio | 28 |
| Lantern Pharma | 24 |
| Passage Bio | 24 |
NRSN News
- 1 day ago - NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout - PRNewsWire
- 7 days ago - PrimeC New Data to Be Presented at AD/PD™ 2026 Conference - PRNewsWire
- 9 days ago - JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity - PRNewsWire
- 16 days ago - PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference - PRNewsWire
- 5 weeks ago - NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS - PRNewsWire
- 6 weeks ago - NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition - PRNewsWire
- 2 months ago - NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease - PRNewsWire
- 2 months ago - World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB - PRNewsWire